FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/10/076067 [Registered on: 29/10/2024] Trial Registered Prospectively
Last Modified On: 29/10/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   In lower limb orthopedic surgeries, comparing the intra operative and post operative, pain relief duration and hemodynamic changes with Buprenorphine versus Butorphenol, when given as additive with 0.5 percent levobupivacaine as spinal anaesthesia. 
Scientific Title of Study   Effectiveness of intrathecal buprenorphine versus butorphanol as adjuvant in 0.5 percent levobupivacaine in lower limb surgeries. 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Chaitanya Bhandari 
Designation  PG Resident 
Affiliation  Institute of Medical Sciences and SUM hospital 
Address  Department of Anaesthesiology and critical care, first floor, IMS and SUM Hospital, K8, Kalinga Nagar, Bhubaneswar

Khordha
ORISSA
751003
India 
Phone  9458900155  
Fax    
Email  Chaitanyabhandari92@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Shaswat Pattnaik 
Designation  Head of Department, Professor 
Affiliation  Institute of Medical Sciences and SUM hospital 
Address  Department of Anaesthesiology and critical care, first floor, IMS and SUM Hospital, K8, Kalinga Nagar, Bhubaneswar

Khordha
ORISSA
751003
India 
Phone  9938303354  
Fax    
Email  hod.anaesthesiology.ims@soa.ac.in  
 
Details of Contact Person
Public Query
 
Name  Dr Shaswat Pattnaik 
Designation  Head of Department, Professor 
Affiliation  Institute of Medical Sciences and SUM hospital 
Address  Department of Anaesthesiology and critical care, first floor, IMS and SUM Hospital, K8, Kalinga Nagar, Bhubaneswar

Khordha
ORISSA
751003
India 
Phone  9938303354  
Fax    
Email  hod.anaesthesiology.ims@soa.ac.in  
 
Source of Monetary or Material Support  
Institute of medical Sciences and SUM Hospital, K8, Kalinga Nagar, Bhubaneswar, Odisha, India, Pin 751003 
 
Primary Sponsor  
Name  Dr Chaitanya Bhandari 
Address  Department of anaesthesiology and critical care, first floor, IMS and SUM Hospital, K8, Kalinga Nagar, Bhubaneswar, Odisha, India, PIN 751003 
Type of Sponsor  Other [self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Chaitanya Bhandari  Institute of Medical Sciences and SUM hoapital  Modular OT 3, first floor, IMS and SUM Hospital, K8, Kalinga Nagar, Bhubaneswar
Khordha
ORISSA 
9458900155

chaitanyabhandari92@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics committee, IMS and SUM Hospital, Bhubaneswar  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: M958||Other specified acquired deformities of musculoskeletal system,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Intrathecal 0.5 percent heavy Levobupivacaine with Buprenorphine  Patients will receive 2.8 ml of 0.5% hyperbaric levobupivacaine with 0.2 ml containing 60 μg Buprenorphene, a total volume of 3 ml intrathecally. Subarachnoid block will be performed under strict aseptic conditions in the sitting position with neck flexed at the level of L3 L4 intervertebral space using 25 G Quinckes spinal needle.The highest level of sensory block will be determined in the midclavicular line bilaterally, by pinprick test using a 20G hypodermic needle every 2 min till the level has stabilized for four consecutive tests. The highest level of sensory block and the time taken to attain it from the time of the intrathecal injection will be recorded. Further sensory testing will be performed at 20 min intervals till the recovery of S2 dermatome. Motor block will be assessed using the modified Bromage scale till achievement of the highest sensory level. At the end of the surgery and then at 30 min intervals till the patient has no motor blockade.Side effects such as hypotension, bradycardia, nausea, vomiting, sedation, pruritis, shivering and respiratory depression were recorded. The time to voiding will also be recorded. The quality of postoperative analgesia will be assessed using LVAS at 15 min, 30 min and thereafter every 30 min, till 2 hours postoperatively, and then every hour, till 4 hours postoperative duration. The time of first request of rescue analgesia will be recorded. Patients reporting an LVAS score of more than or equal to 4 will be treat with 15mg per kg PARACETAMOL IV infusion, as rescue analgesic. Intraoperatively, HR, SBP, DBP, RR and SpO2 will be recorded at 3 minutes intervals for the first 30 min from the time of injection of spinal solution and there after every 15 min for the complete period of surgery.  
Comparator Agent  Intrathecal 0.5 percent heavy Levobupivacaine with Butorphenol  Patients will receive 2.8 ml of 0.5% hyperbaric levobupivacaine with 0.2 ml containing 20 μg butorphanol, a total volume of 3 ml intrathecally. Subarachnoid block will be performed under strict aseptic conditions in the sitting position with neck flexed at the level of L3 L4 intervertebral space using 25 G Quinckes spinal needle.The highest level of sensory block will be determined in the midclavicular line bilaterally, by pinprick test using a 20G hypodermic needle every 2 min till the level has stabilized for four consecutive tests. The highest level of sensory block and the time taken to attain it from the time of the intrathecal injection will be recorded. Further sensory testing will be performed at 20 min intervals till the recovery of S2 dermatome. Motor block will be assessed using the modified Bromage scale till achievement of the highest sensory level. At the end of the surgery and then at 30 min intervals till the patient has no motor blockade.Side effects such as hypotension, bradycardia, nausea, vomiting, sedation, pruritis, shivering and respiratory depression were recorded. The time to voiding will also be recorded. The quality of postoperative analgesia will be assessed using LVAS at 15 min, 30 min and thereafter every 30 min, till 2 hours postoperatively, and then every hour, till 4 hours postoperative duration. The time of first request of rescue analgesia will be recorded. Patients reporting an LVAS score of more than or equal to 4 will be treat with 15mg per kg PARACETAMOL IV infusion, as rescue analgesic. Intraoperatively, HR, SBP, DBP, RR and SpO2 will be recorded at 3 minutes intervals for the first 30 min from the time of injection of spinal solution and there after every 15 min for the complete period of surgery.  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1. Patients undergoing elective lower surgeries.
2. Patient within the age group of 18-60 years
3. Patients under ASA I and II

 
 
ExclusionCriteria 
Details  . Patients under ASA III, ASA IV.
2. Patients with coagulation disorders
3. Patient known allergic to local anesthetic agents
4. Skin infection at local sites
5. Patients who are not willing to participate.
6. Any patient with neurological disorder
 
 
Method of Generating Random Sequence   Stratified block randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
1.Assess the sensory and motor blockade intra operative and post operative after intrathecal Infiltration of 0.5 percent levobupivacaine with adjuvant butorphenol and buprenorphine.
2.To assess the intensity of pain using visual analogue score.
3.Duration of analgesia.
4.Time of first dose of rescue analgesia
 
2,4,6,8,10,12,14,30,90,120 minutes then 1 hourly until sensory blockade reaches S2 dermatome. 
 
Secondary Outcome  
Outcome  TimePoints 
Assessment of intra-op effects of above combination
1. Bradycardia
2. Hypotension
3. Sedation
4. Nausea/vomiting
5. Respiratory depression
6. Shivering
7. Dry mouth, pruritis
8. Urinary retention
 
3 minute interval for first 30 minutes then every 30 minutes then 2 hours post operatively 
 
Target Sample Size   Total Sample Size="105"
Sample Size from India="105" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3/ Phase 4 
Date of First Enrollment (India)   11/11/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

This prospective, randomized, double blind study will be conducted after approval from the institutional ethics committee and informed written consent of patients will be taken. A study of 105 patients, aged 18-60 years, belonging to ASA physical status 1 or 2 and scheduled for elective lower limb orthopedic surgeries will be randomized into three groups using random numbers generated by the computer. Patients in group A (Gp A) will receive 2.8 ml of 0.5% hyperbaric levobupivacaine with 0.2 ml (containing 20 μg) butorphanol, a total volume of 3 ml intrathecally. Similarly, 60 μg of buprenorphine will be added to 2.8 ml of 0.5% hyperbaric levobupivacaine to make a total volume of 3 ml to be given intrathecally to patients in group B (Gp B) and Group C (Gp C) will receive 0.5% heavy levobupivacaine with preservative free NS to make total volume of 3ml.

All patients will undergo a complete general physical examination and systemic examination and will be explained the linear visual analogue scale (LVAS) scoring system for pain during the pre-anaesthetic check-up. The LVAS used is a 11-cm line where 0 denote “no pain” while 10 denote “worst pain imaginable”.

Patients in whom spinal anaesthesia or the study drugs are contraindicated will be excluded from the study. Patients with neurological disease, spinal deformities, local skin infection or mental disorders; those who were morbidly obese, hemodynamically unstable or had coagulation disorders, or patients with liver disease, impaired renal functions, ASA Physical status >2 or a history of opioid dependence will also be excluded from the study.

Patients will be kept fasting for 8 hours to solids and 4 hours to clear fluids preoperatively and receive no premedication. In the operation theatre, an intravenous line will be established. The intrathecal drugs will be prepared by a trained pharmacist beforehand to maintain the blinding process. Baseline heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), respiratory rate (RR) and peripheral arterial oxygen saturation (SpO2) will be recorded for all subjects. All patients will receive 10 ml/kg of ringer lactate solution as preload within 20- 30 minutes. The primary investigator will enter the operation theatre after this period and will be blinded to the patient allocation. All spinal blocks will be given by the same anaesthesiologist. Subarachnoid block will be performed under strict aseptic conditions in the sitting position with neck flexed at the level of L 3-4 inter vertebral space using 25 G Quincke’s spinal needles. The midline approach will be used to perform the spinal blocks after infiltrating the skin with 2% Lidocaine. The test drug will be injected over 15 seconds. Following the subarachnoid block, the patient will be put in supine position.

Intraoperatively, HR, SBP, DBP, RR and SpO2 will be recorded at 3 minutes (min) intervals for the first 30 min from the time of injection of spinal solution and there after every 15 min for the complete period of surgery. This data will be recorded by the attending anaesthesiologist and the primary investigator, who were unaware of the patient allocation. Hypotension (MAP <60 mmHg) will be treated with fluid boluses and 6 mg intravenous (IV) boluses of ephedrine, while bradycardia (HR <50bpm) will be treated with 0.6 mg IV atropine. Respiratory depression is defined as a respiratory rate <8 breaths/min or a SpO2 of <90% on room air. All patients will be given supplemental O2 via face mask at 6 l/min if the SpO2 decreased below 90%.

The highest level of sensory block will be determined in the midclavicular line bilaterally, by pinprick test using a 20-G hypodermic needle every 2 min till the level has stabilized for four consecutive tests. The highest level of sensory block and the time taken to attain it from the time of the intrathecal injection will be recorded. Further sensory testing will be performed at 20-min intervals till the recovery of S2 dermatome. Motor block will be assessed using the modified Bromage scale (grade 0 = no motor block; grade 1 = inability to raise extended legs, able to move knees and feet; grade 2 = inability to raise extended leg and move knee, able to move feet and grade 3 = complete motor block of the lower limbs) till achievement of the highest sensory level; at the end of the surgery and then at 30 min intervals till the patient has no motor blockade.

Side effects such as hypotension, bradycardia, nausea, vomiting, sedation, pruritis, shivering and respiratory depression were recorded. The time to voiding will also be recorded. The quality of postoperative analgesia will be assessed using LVAS at 15 min, 30 min and thereafter every 30 min, till 2 hours postoperatively; and then every hour, till 4 hours postoperative duration. The time of first request of rescue analgesia will be recorded. Patients reporting an LVAS score of ≥4 will be treat with 15mg/kg PARACETAMOL IV infusion, as rescue analgesic.

The data will be compiled using Microsoft excel (2019) and will be analyzed using paired/unpaired t tests and Fisher’s exact tests on the Epi Info software (version 8.0) to assess the statistical difference between the groups. A P value of <0.05 will be accepted as statistically significant.
 
Close